Home Page - ChinaBio® Today

The finalists will present to a judges panel made up of venture capitalists, scientists, industry executives and others. There will also be industry experts speaking on the industry and entrepreneurships. The event will end with the prize ceremony followed by a reception. Attendees will include the finalists, other entrants, government representatives, industry executives, venture capitalists and investors, delegates from the press and interested parties from life science companies and universities.

>> See www.SEED2010.com for more information on the SEED events

ChinaBio® Today - Focused solely on China biotech...

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotechnology companies and industry events, as well as global issues affecting the China life science market.

Email subscriptions are free. Just click here to register for free daily summaries of key events in China biotech. Paid subscriptions provide full access to all articles and analysis, including the over 2000 articles we've published on the biotech industry over the last four years. There is also an option to contact our analysts to answer your questions. Click here to learn more about our subscription plans.

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

AutekBio to Build Largest Biologic CMO in Asia (in: Deals & Financings) Mar 9, 2010: AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing. To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group. More details...

WuXi PharmaTech Reports Solid Performance in 2009 (in: News & Analysis) Mar 8, 2010: As expected, WuXi PharmaTech (药明康德) reported 2009 net revenues of $270 million, an increase of 7%. Net income climbed to $52.9 million compared to a loss of $64.2 million in 2008, when the company took a significant $49.3 million writedown of its US-based biologics manufacturing business, which was part of its AppTec acquisition. Revenues matched analysts’ expectations, while earnings were slightly below forecasts. More details...

Stock Symbol: (NYSE: WX)

The Week in Review: China Life Science to Grow 22% Per Year Through 2013 (in: Week in Review) Mar 6, 2010: IMS Health predicts China’s drug market will see a 22% CAGR during 2010-2113, compared to 4%-6% worldwide; fifteen early stage China life science entrepreneurs were selected as Finalists in the SEED Competition; Chi-Med may IPO its drug development arm, Hutchison MediPharma, possibly on Nasdaq; WuXi PharmaTech (药明康德) struck a two-way pre-clinical services deal with a J&J subsidiary; aTyr Pharma received a second 18-month grant to fund research at its Hong Kong subsidiary; Sanofi-Aventis is seeking additional partnerships in China; Asymchem Labs will build another manufacturing plant in TEDA; Mindray Medical (迈瑞医疗国际有限公司), released very positive financial results and raised $150 million in new cash; Biostar Pharma expects a 35% increase in 2010 revenues; and Kalen Biomedical found a China distribution partner for its research products. More details…

Stock Symbols: (NYSE: RX) (AIM: HCM) (NYSE: WX) (NYSE: JNJ) (NYSE: SNY) (NYSE: MR) (OTCBB: BSPM)

SEED Competition for China Life Science Announces Finalists (in: News & Analysis) Mar 5, 2010: Fifteen entrepreneurs from a broad spectrum of life science fields were selected as Finalists in the SEED Competition, which makes them eligible to compete for the Grand Prize of 300,000 RMB ($45,000). The awards were made at the SEED Finalist Coaching Day event held in Shanghai’s Zhangjiang Hi-Tech Park earlier this week. Over 140 people attended the event. Roche, OrbiMed, and McKinsey organized the SEED competition, which was managed and presented by ChinaBio® Accelerator. More details...

Stock Symbol: (SW: ROG)

Hutchison MediPharma May IPO within Two Years (in: Deals & Financings) Mar 5, 2010: Chi-Med plans to spin off its drug development arm, Hutchison MediPharma, within two years, possibly through an IPO on the Nasdaq exchange. According to the company, the offering would be the largest Nasdaq IPO of a China biotech. At the same time, Hutchison MediPharma is seeking a partner for its lead product, HMPL-004, a treatment for ulcerative colitis that recently released positive results from a Phase IIb trial in the US. More details...

Stock Symbol: (AIM: HCM)

Mindray Raises $152.8 Million in Secondary Offering (in: Deals & Financings) Mar 5, 2010: Mindray Medical (迈瑞医疗国际有限公司),, the medical device company, priced a secondary offering of 4 million American depositary shares at $38.20 per ADS, raising $152.8 million in new cash. Mindray closed the previous trading session at $38.00. Because Mindray seems to have plenty of cash, the offering was a surprise, and may indicate the company is eyeing some future acquisitions. More details...

Stock Symbol: (NYSE: MR)

China Pharmaceutical Market Growing at 22% Clip (in: Industry Insights) Mar 4, 2010: China’s life science industry is growing quickly, and most experts in the prediction industry place the rate of growth at about 20%, a very healthy number. IMS Health, a global pharmaceutical consultancy, expects slightly better results for China: 22% compound annual growth rate during 2010-2013. That compares to a 4% to 6% rate in the global market. In fact, IMS Health thinks China will be responsible for 21% of all growth in the global pharmaceutical market in the next four years. More details...

Stock Symbol: (NYSE: RX)

Sanofi-Aventis Looking for More China Partnerships (in: News & Analysis) Mar 4, 2010: Sanofi-Aventis wants to continue building its presence in China. Company officials said Sanofi-Aventis will seek additional partnerships following the joint venture announced last month with Minsheng Pharmaceutical, a JV that will develop vitamin and mineral products in the consumer healthcare sector. Sanofi has gone on record to say it prefers the partnership approach in China, as opposed to building its own R&D center. More details...

Stock Symbol: (NYSE: SNY)

Asymchem Plans Another Facility at TEDA (in: News & Analysis) Mar 3, 2010: Asymchem Laboratories, a North Carolina company with an extensive network of CMO facilities in China, has agreed to build another manufacturing plant in the Tianjin Economic-Technological Development Area (TEDA), according to China Knowledge. This project will focus on R&D, production and distribution of biomedical products. More details...

Generex Granted China Patent for Cancer Vaccine (in: News & Analysis) Mar 3, 2010: Generex Biotechnology announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. Generex is “actively seeking” either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas. More details...

Stock Symbol: (NSDQ: GNBT)